Insomnia Market

Growing social media promotions and celebrity endorsements to boost the market growth

The prevalence of different types of sleep disorders, such as insomnia and parasomnias, an increase in mental depression, and other painful conditions drives the growth of the  insomnia market size. Mental depression results in difficulty in sleep. For instance, the World Health Organization (WHO) reported that around 280 million population ly suffers from depression. Thus, the increase in mental depression across the  population enhanced the market CAGR across the globe in recent years.

Furthermore, long-term medication consumption for chronic disease treatment has some side effects, which are believed to affect the patient's quality of sleep. Thus, an increase in the prevalence of chronic diseases, such as cancer, drives the growth of the market. For instance, according to the National Institute of Cancer (NIC), an estimated 1,806,590 new cancer cases were diagnosed in the US in 2020. Cancer chemotherapy results in various side effects on the patient's body and affects the quality of sleep in patientsdriving the growth of the insomnia market revenue.

In addition, the surge in work-related stress contributes to the maket growth of the insomnia. The rise in workload and hectic work schedules lead to poor quality of sleep. Many people work odd shifts, such as security officers, and the manufacturing industries operate for 24 hours. These odd-time work shifts affect the quality and cycle of sleep. An increase in the number of insomnia centers and sleep diagnostic centers contributes to the growth of the market. Insomnia centers assist people in improving their sleep quality, and sleep diagnostic centers are used as a diagnostic labs for detecting sleep disorders.

Furthermore, increasing the adoption of non-pharmacological sleep therapy drives the market's growth. Insomnia is commonly associated with the mental condition of the person. Hence, non-pharmacological therapy, such as hypnotherapy, yoga, and cognitive behavioral therapy, focuses on improving a person's mental state and driving the insomnia industry.

The aging population is a significant driver of the Global Insomnia Market Industry. As individuals age, they often experience changes in sleep patterns and an increased prevalence of insomnia. Data indicates that older adults are more susceptible to sleep disorders, with nearly 50 percent of seniors reporting insomnia symptoms. This demographic shift is expected to contribute to the market's growth, as the demand for tailored treatment options for older adults rises. The Global Insomnia Market Industry is likely to adapt to these needs, ensuring that effective solutions are accessible to this vulnerable population.

The Global Insomnia Market Industry is projected to experience substantial growth over the next decade. With a market value of 5.22 USD Billion in 2024, it is anticipated to reach 10.2 USD Billion by 2035. This growth trajectory reflects a compound annual growth rate of 6.31 percent from 2025 to 2035, indicating a robust demand for insomnia treatments and solutions. The increasing prevalence of sleep disorders, coupled with advancements in treatment options and heightened awareness of sleep health, is likely to drive this market expansion. The Global Insomnia Market Industry is positioned for significant development in the coming years.

The Global Insomnia Market Industry is witnessing a notable increase in the prevalence of insomnia, driven by various factors such as stress, anxiety, and lifestyle changes. According to recent data, approximately 30 percent of adults globally report experiencing insomnia symptoms, which significantly contributes to the growing demand for treatment options. This trend is expected to propel the market value to 5.22 USD Billion in 2024, reflecting a heightened awareness of sleep disorders and their impact on overall health. As more individuals seek effective solutions, the Global Insomnia Market Industry is poised for substantial growth.

Innovations in treatment modalities are transforming the Global Insomnia Market Industry. The emergence of new pharmacological therapies, cognitive behavioral therapy, and digital health solutions are providing patients with diverse options to manage their insomnia. For instance, the introduction of non-benzodiazepine sleep aids has gained traction due to their favorable safety profiles. These advancements not only enhance patient outcomes but also stimulate market growth, as evidenced by the projected increase in market size to 10.2 USD Billion by 2035. The continuous development of effective treatments is likely to attract more consumers to the Global Insomnia Market Industry.

There is a growing recognition of the importance of sleep health within the Global Insomnia Market Industry. Public health campaigns and educational initiatives are raising awareness about the detrimental effects of insomnia on physical and mental well-being. This heightened awareness is encouraging individuals to seek professional help and explore available treatment options. As a result, the market is expected to experience a compound annual growth rate of 6.31 percent from 2025 to 2035. The focus on sleep health is likely to drive demand for insomnia-related products and services, further expanding the Global Insomnia Market Industry.

The integration of technology into sleep solutions is reshaping the Global Insomnia Market Industry. Wearable devices, sleep tracking applications, and telehealth services are becoming increasingly popular among consumers seeking to improve their sleep quality. These technological advancements provide users with personalized insights and recommendations, fostering better sleep hygiene. The convenience and accessibility of these solutions are likely to drive market growth, as more individuals turn to technology for assistance in managing insomnia. The Global Insomnia Market Industry is expected to benefit from this trend as it evolves to incorporate innovative technological solutions.

By Region, the study deliversmarket insights into North America, Asia-Pacific, Europe and the Rest of the World. The North America insomnia market accounted for USD 0.68billion in 2022 and is anticipated to exhibit a significant CAGR growth during the study period. Growing demand for sleep disorder treatment in the US and Canada and an increasing prevalence of sleep disorders increased awareness and high healthcare spending in the region. Further, the US market of insomnia held the largest market share, and the Canada market of insomnia was the fastest-growing market in the North Americaregion.

Further, the prominent countries studied in the market report are The U.S, Canada, France, the UK, Italy, Germany, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2 INSOMNIA MARKET SHARE BY REGION 2022 (%)

Source Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Europe insomnia market accounts for the second-largest market share over the forecast period. This is attributed to the increasing prevalence of sleep disorders, the existence of major market players, and frequent product introduction coupled with increasing government funding for insomnia treatments. Further, the Germany market of insomnia held the largest market share, and the UK market of insomnia was the fastest-growing market in the Europe region.

The Asia-Pacific Insomnia market is expected to grow at the fastest CAGR from 2024 to 2032. This is owing to the high prevalence of the target disease, and it is estimated that one out of five people in Japan suffer from it. Emerging economies such as India, China, and Indonesia have been using generics and branded generics due to the economic pricing of generic alternatives. Moreover, the China market of insomnia held the largest market share, and the India market of insomnia was the fastest-growing market in the Asia-Pacific region.

Major market players are expending a lot of money on R&D to enhance their product lines, which will allow the market of insomnia to grow even more. Major market participants are also taking various strategic initiatives to expand their worldwide footprint, with key market developments such as new contractual agreements, product launches, mergers and acquisitions, improved investments, and collaboration with other organizations. Competitors in the insomnia industry must offer cost-effective items to enhance and survive in an increasingly competitive and growing market environment.

Manufacturing locally to reduce operating costs is one of the primary enterprise strategies manufacturers adopt in the insomnia industry to benefit clients and expand the market sector. The insomnia market major player such as Pfizer Inc. (UK), Sanofi (France), GlaxoSmithKline Plc. (UK), and others are working on enhancing the market demand by investing in R&D activities.

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical firm. It primarily focuses on developing and commercializing a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. In January 2021, Royalty Pharma PLC and Minerva Neurosciences Inc. entered an agreement via which Royalty Pharma will receive Minerva's royalty interest in seltorexant. It is a selective orexin two receptor antagonist and is presently in Phase 3 development for treating primary depressive disorder (MDD) with insomnia symptoms.

Also, Eisai Co., Ltd. produces prescription drugs and medical equipment and sells mainly to sales agents and subsidiaries. Through its subsidiary, the Company produces and sells diagnostic drugs. Eisai also markets its products through related companies in the US, Europe, and Asia. The Company also manufactures and sells foods, livestock feeds, chemicals, and agrochemicals. In February 2021, Eisai Limited is, the Canadian subsidiary of Eisai Inc. approved Canadian authorization for its new non-sedative prescription medication, DAYVIGO (lemborexant).

In both 10 mg and 5 mg dosages, DAYVIGO is taken for the therapy of insomnia, characterized by problems with sleep onset and/or sleep maintenance.